This study is a post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Ciproxan intravenously as a first-line treatment for sepsis, secondary skin infections followed by superficial burn, post-surgical or post-traumatic, pneumonia, peritonitis, cholecystitis, cholangitis, anthrax. The objective of this study is to assess safety and efficacy of Ciproxan in daily clinical practice. A total of 3,000 patients are to be enrolled and assessed during the period of treatment with Ciproxan.
Study Type
OBSERVATIONAL
Enrollment
3,274
Patient treated with Ciproxan as a first line treatment in daily clinical practice
Unnamed facility
Many Locations, Japan
Incidence of adverse drug reactions (ADRs) and serious adverse events (AEs)
Time frame: After 9 days
Clinical efficacy by four grade (Response, Minor Response, No Response, and Indeterminable) at an investigator discretion
Time frame: After 9 days
ADR incidence rates classified by patient's background factors
Time frame: After 9 days
Efficacy rate calculated with Response and Minor Response considered as responder
Time frame: After 9 days
Efficacy rates classified by patient's background factors
Time frame: After 9 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.